StradBio, Inc.

StradBio is creating the next generation of immunotherapies by using computationally designed, precision-tuned
immune agonists. Systemic toxicity in immunotherapy development has limited the ability to achieve therapeutic doses for immune agonists. The venture’s computationally-designed cytokine mimetics have a broader range of potencies and can be engineered to create logic gates to regulate activation and widen the therapeutic windows, enabling highly targeted immune activation with a high therapeutic index, and making treatments more suitable for outpatient care.